Gastrointestinal Cancer | Specialty

Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers

June 21st 2018

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

Dr. Kim on PRODIGE 37 in Pancreatic Cancer

June 21st 2018

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers

June 21st 2018

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

Conroy Highlights Practice-Changing Findings With Chemo Combo in Pancreatic Cancer

June 21st 2018

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.

TAS-120 Shows Promise in Cholangiocarcinoma

June 21st 2018

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

Adding SIRT Does Not Provide Survival Benefit in Advanced HCC, Except in Select Patients

June 20th 2018

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.

Advanced CRC: Pushing the Treatment Paradigm Forward

June 20th 2018

Discerning HIPEC

June 20th 2018

Advanced CRC: Liquid Biopsies and the CRICKET Study

June 20th 2018

VALENTINO Study: Maintenance Therapy in Advanced CRC

June 20th 2018

Combination Strategies in Advanced CRC: E7208 and APOLLON

June 20th 2018

Key Investigations in Advanced Colorectal Cancer

June 20th 2018

Ramucirumab Extends Survival for AFP-Elevated HCC in Pooled Analysis

June 20th 2018

Treatment with second-line ramucirumab improved median overall survival by 3.1 months compared with placebo in patients with advanced hepatocellular carcinoma with alpha-fetoprotein levels ≥400 ng/ml.

Dr. Conroy Discusses Survival Data With FOLFIRINOX in Pancreatic Cancer

June 20th 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX in pancreatic cancer.

Dr. Finn Discusses the Pooled Analysis of REACH and REACH-2 in HCC

June 20th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

Dr. Bekaii-Saab on Immunotherapy in Colorectal Cancer

June 18th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of immunotherapy in patients with microsatellite stable colorectal cancer.

Adjuvant Chemotherapy Advances Boost Outcomes in GI Malignancies

June 18th 2018

Diane Reidy-Lagunes, MD, outlines the current state-of-the-art gastrointestinal care.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Status Report: Expert Reviews Guideline-Based Options in Advanced CRC

June 13th 2018

There are pivotal developments in colorectal cancer that have shaped the National Comprehensive Cancer Network guidelines in the past several years.

It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRC

June 11th 2018

Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.